Overview

Tysabri Observational Program

Status:
Active, not recruiting
Trial end date:
2029-01-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the long-term safety and impact on disease activity and progression of natalizumab in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.
Details
Lead Sponsor:
Biogen
Treatments:
Natalizumab